{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:56:27Z","timestamp":1791374187327,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"DOI":"10.1007\/s41999-026-01621-9","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:36:52Z","timestamp":1791373012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Very late-onset myasthenia gravis: a systematic review and meta-analysis of clinical severity and long-term outcomes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2958-5220","authenticated-orcid":false,"given":"Ioannis","family":"Liampas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Demiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Polyviou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D\u2019Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Siokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Veltsista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthimios","family":"Dardiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Chroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.irn.2025.04.028","volume":"182","author":"NE Gilhus","year":"2025","unstructured":"Gilhus NE, Breiner A (2025) Epidemiology of myasthenia gravis. Int Rev Neurobiol 182:161\u2013196. https:\/\/doi.org\/10.1016\/bs.irn.2025.04.028","journal-title":"Int Rev Neurobiol"},{"key":"1621_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08164622.2022.2029683","volume":"105","author":"NH Shuey","year":"2022","unstructured":"Shuey NH (2022) Ocular myasthenia gravis: a review and practical guide for clinicians. Clin Exp Optom 105:205\u2013213. https:\/\/doi.org\/10.1080\/08164622.2022.2029683","journal-title":"Clin Exp Optom"},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A (2025) New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs 39:185\u2013213. https:\/\/doi.org\/10.1007\/s40259-024-00701-1","journal-title":"BioDrugs"},{"key":"1621_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1277420","volume":"15","author":"J Moura","year":"2024","unstructured":"Moura J, Fernandes J, Lima MJ, Sousa AP, Sam\u00f5es R, Martins Silva A et al (2024) Treatment strategies and treatment-related adverse events in MG according to the age of onset. Front Neurol 15:1277420. https:\/\/doi.org\/10.3389\/fneur.2024.1277420","journal-title":"Front Neurol"},{"key":"1621_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16367","volume":"9","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M, Mantegazza R, Rodolico C, Sacc\u00e0 F et al (2023) Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon 9:e16367. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367","journal-title":"Heliyon"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.irn.2025.08.001","volume":"183","author":"P Narayanaswami","year":"2025","unstructured":"Narayanaswami P, Verity R, Vissing J (2025) Novel treatments for myasthenia gravis. Int Rev Neurobiol 183:133\u2013160. https:\/\/doi.org\/10.1016\/bs.irn.2025.08.001","journal-title":"Int Rev Neurobiol"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/bs.irn.2025.04.032","volume":"182","author":"S Hoffmann","year":"2025","unstructured":"Hoffmann S (2025) Special populations in myasthenia gravis: early, late, and very late-onset MG. Int Rev Neurobiol 182:197\u2013204. https:\/\/doi.org\/10.1016\/bs.irn.2025.04.032","journal-title":"Int Rev Neurobiol"},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00415-026-14014-6","volume":"273","author":"I Liampas","year":"2026","unstructured":"Liampas I, Demiri S, Malataras G, Polyviou A, Siokas V, Veltsista D et al (2026) Very late-onset myasthenia gravis: a systematic review and meta-analysis of sex distribution, thymic pathology and autoantibodies. J Neurol 273:466. https:\/\/doi.org\/10.1007\/s00415-026-14014-6","journal-title":"J Neurol"},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/med-23-43","volume":"8","author":"W Waheed","year":"2024","unstructured":"Waheed W, Bacopulos A, Seyam M, Kooperkamp H, Moin M, Malik T et al (2024) Physiological and pathological roles of the thymus and value of thymectomy in myasthenia gravis: a narrative review. Mediastinum 8:31. https:\/\/doi.org\/10.21037\/med-23-43","journal-title":"Mediastinum"},{"key":"1621_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ITT.S261414","volume":"9","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P (2020) Complement Inhibition for the treatment of myasthenia gravis. Immunotargets Ther 9:317\u2013331. https:\/\/doi.org\/10.2147\/ITT.S261414","journal-title":"Immunotargets Ther"},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/ggi.70046","volume":"25","author":"H Umegaki","year":"2025","unstructured":"Umegaki H (2025) Frailty, multimorbidity, and polypharmacy: proposal of the new concept of the geriatric triangle. Geriatr Gerontol Int 25:657\u2013662. https:\/\/doi.org\/10.1111\/ggi.70046","journal-title":"Geriatr Gerontol Int"},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A et al (2020) Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology 94:e1171\u2013e1180. https:\/\/doi.org\/10.1212\/WNL.0000000000008903","journal-title":"Neurology"},{"key":"1621_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1641701","volume":"16","author":"I Liampas","year":"2025","unstructured":"Liampas I, Veltsista D, Batzikosta P, Lazarou L, Kefalopoulou ZM, Chroni E (2025) The short-term prognosis of very late onset generalized myasthenia gravis: a single-center retrospective cohort study. Front Neurol 16:1641701. https:\/\/doi.org\/10.3389\/fneur.2025.1641701","journal-title":"Front Neurol"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012. https:\/\/doi.org\/10.1001\/jama.283.15.2008","journal-title":"JAMA"},{"key":"1621_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"1621_CR16","unstructured":"Homepage | Ottawa Hospital Research Institute n.d. https:\/\/ohri.ca\/en (Accessed 31 Aug 2026)"},{"key":"1621_CR17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2013.03.003","volume":"66","author":"L Hartling","year":"2013","unstructured":"Hartling L, Milne A, Hamm MP, Vandermeer B, Ansari M, Tsertsvadze A et al (2013) Testing the Newcastle Ottawa scale showed low reliability between individual reviewers. J Clin Epidemiol 66:982\u2013993. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.03.003","journal-title":"J Clin Epidemiol"},{"key":"1621_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America et al (2000) Myasthenia gravis. Neurology 55:16\u201323. https:\/\/doi.org\/10.1212\/WNL.55.1.16","journal-title":"Neurology"},{"key":"1621_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.neurol.2019.12.008","volume":"176","author":"I Liampas","year":"2020","unstructured":"Liampas I, Siokas V, Brotis A, Dardiotis E (2020) Vitamin D serum levels in patients with migraine: a meta-analysis. Rev Neurol 176:560\u2013570. https:\/\/doi.org\/10.1016\/j.neurol.2019.12.008","journal-title":"Rev Neurol"},{"key":"1621_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-020-00091-z","volume":"2","author":"F Pasqualin","year":"2020","unstructured":"Pasqualin F, Guidoni SV, Ermani M, Pegoraro E, Bonifati DM (2020) Outcome measures and treatment effectiveness in late onset myasthenia gravis. Neurol Res Pract 2:45. https:\/\/doi.org\/10.1186\/s42466-020-00091-z","journal-title":"Neurol Res Pract"},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.5498\/wjp.v12.i3.470","volume":"12","author":"L Yu","year":"2022","unstructured":"Yu L, Qiu L, Ran H, Ma Q, Lu Y-R, Liu W-B (2022) Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients. World J Psychiatry 12:470\u2013482. https:\/\/doi.org\/10.5498\/wjp.v12.i3.470","journal-title":"World J Psychiatry"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.nmd.2023.02.013","volume":"33","author":"Y-L Tang","year":"2023","unstructured":"Tang Y-L, Ruan Z, Su Y, Guo R-J, Gao T, Liu Y et al (2023) Clinical characteristics and prognosis of very late-onset myasthenia gravis in China. Neuromuscul Disord 33:358\u2013366. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.013","journal-title":"Neuromuscul Disord"},{"key":"1621_CR23","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s10072-021-05599-z","volume":"43","author":"Y Li","year":"2022","unstructured":"Li Y, Dong X, Li Z, Peng Y, Jin W, Zhou R et al (2022) Characteristics of myasthenia gravis in elderly patients: a retrospective study. Neurol Sci 43:2775\u20132783. https:\/\/doi.org\/10.1007\/s10072-021-05599-z","journal-title":"Neurol Sci"},{"key":"1621_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clineuro.2007.05.023","volume":"109","author":"KH Chan","year":"2007","unstructured":"Chan KH, Cheung RTF, Mak W, Ho SL (2007) Nonthymoma early-onset- and late-onset-generalized myasthenia gravis--a retrospective hospital-based study. Clin Neurol Neurosurg 109:686\u2013691. https:\/\/doi.org\/10.1016\/j.clineuro.2007.05.023","journal-title":"Clin Neurol Neurosurg"},{"key":"1621_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ensci.2016.02.004","volume":"2","author":"W Sakai","year":"2016","unstructured":"Sakai W, Matsui N, Ishida M, Furukawa T, Miyazaki Y, Fujita K et al (2016) Late-onset myasthenia gravis is predisposed to become generalized in the elderly. eNeurologicalSci 2:17\u201320. https:\/\/doi.org\/10.1016\/j.ensci.2016.02.004","journal-title":"eNeurologicalSci"},{"key":"1621_CR26","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","volume":"259","author":"SA Zivkovi\u0107","year":"2012","unstructured":"Zivkovi\u0107 SA, Clemens PR, Lacomis D (2012) Characteristics of late-onset myasthenia gravis. J Neurol 259:2167\u20132171. https:\/\/doi.org\/10.1007\/s00415-012-6478-6","journal-title":"J Neurol"},{"key":"1621_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2026.2648293","author":"I Liampas","year":"2026","unstructured":"Liampas I, Kimiskidis VK, Zouvelou V, Veltsista D, Moscholouri A, Triantafyllou E et al (2026) Clinical parameters affecting the course of amyotrophic lateral sclerosis: a longitudinal analysis of the Greek registry for amyotrophic lateral sclerosis (ALS-GR). Amyotroph Later Scler Frontotemporal Degener. https:\/\/doi.org\/10.1080\/21678421.2026.2648293","journal-title":"Amyotroph Later Scler Frontotemporal Degener"},{"key":"1621_CR28","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s10072-024-07920-y","volume":"46","author":"AG Vakrakou","year":"2025","unstructured":"Vakrakou AG, Strataki E, Lymperopoulos L, Panaretos D, Zouvelou V (2025) Phenotypic patterns and response to immunotherapy in a group of very late onset myasthenia gravis: a single center study. Neurol Sci 46:1833\u20131842. https:\/\/doi.org\/10.1007\/s10072-024-07920-y","journal-title":"Neurol Sci"},{"key":"1621_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13613-025-01515-2","volume":"15","author":"C Marois","year":"2025","unstructured":"Marois C, Combes A, Bouguerra M, Grinea A, Meglio LD, Rambaud T et al (2025) Weaning from mechanical ventilation in myasthenic crisis according to WEAN safe: most patients experience intermediate or prolonged weaning with no differences between early and late-onset compared to very-late onset myasthenia gravis. Ann Intensive Care 15:95. https:\/\/doi.org\/10.1186\/s13613-025-01515-2","journal-title":"Ann Intensive Care"},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.26169","volume":"90","author":"L Handunnetthi","year":"2021","unstructured":"Handunnetthi L, Knezevic B, Kasela S, Burnham KL, Milani L, Irani SR et al (2021) Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease. Ann Neurol 90:455\u2013463. https:\/\/doi.org\/10.1002\/ana.26169","journal-title":"Ann Neurol"},{"key":"1621_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.199679","volume":"11","author":"J Theorell","year":"2026","unstructured":"Theorell J, Ruffin N, Fower A, Sorini C, Ambrose P, Damato V et al (2026) Cellular immune endophenotypes separating early and late-onset myasthenia gravis. JCI Insight 11:e199679. https:\/\/doi.org\/10.1172\/jci.insight.199679","journal-title":"JCI Insight"},{"key":"1621_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110499","volume":"14","author":"R Huda","year":"2023","unstructured":"Huda R (2023) Inflammation and autoimmune myasthenia gravis. Front Immunol 14:1110499. https:\/\/doi.org\/10.3389\/fimmu.2023.1110499","journal-title":"Front Immunol"},{"key":"1621_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep25886","volume":"6","author":"A Uzawa","year":"2016","unstructured":"Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K, Kuwabara S (2016) Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep 6:25886. https:\/\/doi.org\/10.1038\/srep25886","journal-title":"Sci Rep"},{"key":"1621_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23745","volume":"10","author":"S-L Wei","year":"2023","unstructured":"Wei S-L, Yang C-L, Si W-Y, Dong J, Zhao X-L, Zhang P et al (2023) Altered serum levels of cytokines in patients with myasthenia gravis. Heliyon 10:e23745. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23745","journal-title":"Heliyon"},{"key":"1621_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111586","volume":"141","author":"Y Ji","year":"2025","unstructured":"Ji Y, Zhou S, He X, Li W, Zhao X, Zhang Y et al (2025) Clinical heterogeneity, treatment patterns, and outcomes of advanced-age-onset myasthenia gravis in China: a retrospective cohort study. J Clin Neurosci 141:111586. https:\/\/doi.org\/10.1016\/j.jocn.2025.111586","journal-title":"J Clin Neurosci"},{"key":"1621_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241309793","volume":"18","author":"N Xie","year":"2025","unstructured":"Xie N, Liu Q, Wen Q, Wang Y, Liu H, Jiang Y et al (2025) Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients. Ther Adv Neurol Disord 18:17562864241309793. https:\/\/doi.org\/10.1177\/17562864241309793","journal-title":"Ther Adv Neurol Disord"},{"key":"1621_CR37","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X415163251205123550","author":"C Ma","year":"2026","unstructured":"Ma C, Shen J, Zhu Y, Wang B, Zhu R (2026) Efgartigimod in very-late-onset generalized myasthenia gravis: a real-world study on effectiveness and safety. Curr Neuropharmacol. https:\/\/doi.org\/10.2174\/011570159X415163251205123550","journal-title":"Curr Neuropharmacol"},{"key":"1621_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1579859","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yang M, Guo X, Ma T, Wang Z, Luo T et al (2025) Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis. Front Immunol 16:1579859. https:\/\/doi.org\/10.3389\/fimmu.2025.1579859","journal-title":"Front Immunol"},{"key":"1621_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70048","volume":"32","author":"J Chen","year":"2025","unstructured":"Chen J, Su C, Feng H, Kaminski HJ (2025) Can non-thymomatous late-onset myasthenia gravis benefit from thymectomy? A systematic review and meta-analysis. Eur J Neurol 32:e70048. https:\/\/doi.org\/10.1111\/ene.70048","journal-title":"Eur J Neurol"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-026-01621-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-026-01621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:36:55Z","timestamp":1791373015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-026-01621-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":39,"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s41999-026-01621-9","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"22 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This systematic review and meta-analysis used data from previously published studies.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}